Cyclic peptides and uses thereof
Novel cyclic peptide GHRP-6 analogs of formula (I): (I) or pharmaceutically acceptable esters or salts thereof, are described. These cyclic peptide GHRP-6 analogs may be used for modulating CD36 activity, for example for the treatment of CD36-related diseases, disorders or conditions in a subject, such as atherosclerosis and age-related macular degeneration.
1. A cyclic peptide that binds to CD36, wherein the cyclic peptide has one of the following structures:
or a pharmaceutically acceptable salt thereof.
2. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
3. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
4. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
5. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
6. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
7. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
8. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
9. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
10. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
11. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
12. The cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , being:
or a pharmaceutically acceptable salt thereof.
13. A method of treating a CD36-related disease, disorder or condition, the method comprising administering to a subject in need thereof an effective amount of the cyclic peptide or pharmaceutically acceptable salt thereof of claim 1 , wherein the CD36-related disease, disorder or condition is atherosclerosis or age-related macular degeneration.
14. The method of claim 13 , wherein said CD36-related disease, disorder or condition is age-related macular degeneration.
15. A method of treating a CD36-related disease, disorder or condition, the method comprising administering to a subject in need thereof an effective amount of the cyclic peptide or pharmaceutically acceptable salt thereof of claim 2 , wherein the CD36-related disease, disorder or condition is atherosclerosis or age-related macular degeneration.